Key Findings
Immunohistochemistry is a comprehensive phrase, integrating biochemical, immunological, and anatomical procedure to visualize and constrain individually separated constituents in tissues by interacting with the antibodies-antigen. The market is anticipated to develop at 7.93% of CAGR throughout the forecasting years.

Market Insights
The growing geriatric population along with the augmenting healthcare expenditure are some of the key factors driving the global immunohistochemistry market. The market segmentation includes product, application, and end-user. In the product market, reagents segment is evolving at a significant pace during the forecast period. The reagents segment of the product market includes histological stains, blocking sera and reagents, chromogenic substrates, fixation reagents, stabilizers, organic solvents, proteolytic enzymes, and diluents. The diagnostics is the fastest growing segment in the application market. Moreover, diagnostic laboratories and hospitals dominate by holding the highest share in the end-user market. Nevertheless, growing undiagnosed populace with no insurance cover is one of the major factor declining the growth of the market across the globe.

Regional Insights
The global immunohistochemistry market comprises of four major regions such as North America, Europe, Asia-Pacific, Latin America, and rest of world. North America region dominates the global market, majorly attributed to the developed countries like the United States and Canada. Moreover, the Asia Pacific region is evolving at a significant pace over the forecasting years. The growing cases of cancer is the major reason driving the market growth in this region.

Competitive Insights
The leading players in the market are Abbott Laboratories, Abcam Plc, Agilent Technologies, Inc., Biogenex, Bio-Rad Laboratories, Inc., Bio Sb, Cell Signaling Technology, Inc., Danaher Corporation, F. Hoffmann-La Roche Ag, Histologix, Merck Millipore, Perkinelmer, Inc., Siemens Ag Healthcare, and Thermo Fisher Scientific Inc.